• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

RUNX1-EVI1可诱导小鼠巨核细胞系发育异常造血及急性白血病。

RUNX1-EVI1 induces dysplastic hematopoiesis and acute leukemia of the megakaryocytic lineage in mice.

作者信息

Nakamura Yuka, Ichikawa Motoshi, Oda Hideaki, Yamazaki Ieharu, Sasaki Ko, Mitani Kinuko

机构信息

Department of Hematology and Oncology, Dokkyo Medical University School of Medicine, Tochigi, Japan.

Department of Pathology, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.

出版信息

Leuk Res. 2018 Nov;74:14-20. doi: 10.1016/j.leukres.2018.09.015. Epub 2018 Sep 26.

DOI:10.1016/j.leukres.2018.09.015
PMID:30278283
Abstract

The RUNX1-EVI1 gene generated by the t(3;21) translocation encodes a chimeric transcription factor and is a causative gene in the development of de novo acute megakaryoblastic leukemia and leukemic transformation of hematopoietic stem cell tumors. Heterozygous RUNX1-EVI1 knock-in mice die in utero due to hemorrhage in the central nervous system and spinal cord and complete abolishment of definitive hematopoiesis in the fetal liver. On the other hand, the chimeric knock-in mouse develops acute megakaryoblastic leukemia. We created another mouse model of RUNX1-EVI1 using transplantation of retrovirus-infected bone marrow cells. Some mice transplanted with RUNX1-EVI1-expressing bone marrow cells developed acute megakaryoblastic leukemia within eight months, and the other non-leukemic mice showed thrombocytosis at around a year. In the non-leukemic mice, dysplastic megakaryocytes proliferated in the bone marrow and frequently infiltrated into the spleen, which was not associated with marrow fibrosis. In the leukemic mice, their tumor cells were positive for c-kit and CD41, and negative for TER119. Although they were negative for platelet peroxidase in the electron microscopic analysis, they had multiple centrioles in the cytoplasm, which are characteristic of megakaryocytes that undergo endomitosis. The leukemic cells were serially transplantable, and gene-expression analyses using quantitative RT-PCR arrays revealed that they showed significantly elevated expression of stem cell, primitive hematopoietic cell and endothelial cell-related genes compared with normal bone marrow cells. All these data suggested that RUNX1-EVI1 caused dysplastic hematopoiesis or leukemia of the megakaryocytic lineage and endowed gene expression profiles distinctive of immature hematopoietic cells.

摘要

由t(3;21)易位产生的RUNX1-EVI1基因编码一种嵌合转录因子,是原发性急性巨核细胞白血病发生以及造血干细胞肿瘤白血病转化中的致病基因。杂合性RUNX1-EVI1基因敲入小鼠因中枢神经系统和脊髓出血以及胎儿肝脏中确定性造血完全消失而在子宫内死亡。另一方面,嵌合基因敲入小鼠会发生急性巨核细胞白血病。我们通过移植逆转录病毒感染的骨髓细胞创建了另一种RUNX1-EVI1小鼠模型。一些移植了表达RUNX1-EVI1骨髓细胞的小鼠在八个月内发生了急性巨核细胞白血病,其他非白血病小鼠在大约一岁时出现血小板增多症。在非白血病小鼠中,发育异常的巨核细胞在骨髓中增殖,并经常浸润到脾脏,这与骨髓纤维化无关。在白血病小鼠中,它们的肿瘤细胞c-kit和CD41呈阳性,TER119呈阴性。尽管在电子显微镜分析中它们的血小板过氧化物酶呈阴性,但它们的细胞质中有多个中心粒,这是经历核内有丝分裂的巨核细胞的特征。白血病细胞可连续移植,使用定量RT-PCR阵列进行的基因表达分析显示,与正常骨髓细胞相比,它们的干细胞、原始造血细胞和内皮细胞相关基因的表达显著升高。所有这些数据表明,RUNX1-EVI1导致巨核细胞系发育异常造血或白血病,并赋予了未成熟造血细胞独特的基因表达谱。

相似文献

1
RUNX1-EVI1 induces dysplastic hematopoiesis and acute leukemia of the megakaryocytic lineage in mice.RUNX1-EVI1可诱导小鼠巨核细胞系发育异常造血及急性白血病。
Leuk Res. 2018 Nov;74:14-20. doi: 10.1016/j.leukres.2018.09.015. Epub 2018 Sep 26.
2
Role of the RUNX1-EVI1 fusion gene in leukemogenesis.RUNX1-EVI1融合基因在白血病发生中的作用。
Cancer Sci. 2008 Oct;99(10):1878-83. doi: 10.1111/j.1349-7006.2008.00956.x.
3
Dysplastic definitive hematopoiesis in AML1/EVI1 knock-in embryos.AML1/EVI1基因敲入胚胎中的发育异常确定性造血作用。
Blood. 2005 Sep 15;106(6):2147-55. doi: 10.1182/blood-2004-11-4330. Epub 2005 May 24.
4
A 5' untranslated region containing the IRES element in the Runx1 gene is required for angiogenesis, hematopoiesis and leukemogenesis in a knock-in mouse model.在一个基因敲入小鼠模型中,Runx1 基因 5' 非翻译区中的 IRES 元件对于血管生成、造血和白血病发生是必需的。
Dev Biol. 2010 Sep 15;345(2):226-36. doi: 10.1016/j.ydbio.2010.07.015. Epub 2010 Jul 18.
5
Fadd and Skp2 are possible downstream targets of RUNX1-EVI1.Fadd 和 Skp2 可能是 RUNX1-EVI1 的下游靶标。
Int J Hematol. 2013 Jan;97(1):83-91. doi: 10.1007/s12185-012-1232-5. Epub 2012 Dec 19.
6
Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription.急性髓系白血病中人类 EVI1 基因启动子区的功能特征:RUNX1 和 ELK1 直接调节其转录。
Oncogene. 2013 Apr 18;32(16):2069-78. doi: 10.1038/onc.2012.222. Epub 2012 Jun 11.
7
Thrombopoietin/MPL signaling confers growth and survival capacity to CD41-positive cells in a mouse model of Evi1 leukemia.血小板生成素/MPL 信号在 Evi1 白血病小鼠模型中赋予 CD41 阳性细胞生长和存活能力。
Blood. 2014 Dec 4;124(24):3587-96. doi: 10.1182/blood-2013-12-546275. Epub 2014 Oct 8.
8
RUNX1-EVI1 disrupts lineage determination and the cell cycle by interfering with RUNX1 and EVI1 driven gene regulatory networks.RUNX1-EVI1 通过干扰 RUNX1 和 EVI1 驱动的基因调控网络,破坏细胞谱系的确定和细胞周期。
Haematologica. 2021 Jun 1;106(6):1569-1580. doi: 10.3324/haematol.2019.241885.
9
The role of EVI1 in normal and leukemic cells.EVI1在正常细胞和白血病细胞中的作用。
Blood Cells Mol Dis. 2003 Sep-Oct;31(2):206-12. doi: 10.1016/s1079-9796(03)00159-1.
10
Repression of RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis.EVI1对RUNX1活性的抑制:EVI1在白血病发生中的新作用。
Cancer Res. 2007 Jun 15;67(12):5658-66. doi: 10.1158/0008-5472.CAN-06-3962.

引用本文的文献

1
Reduced-intensity conditioning is effective for allogeneic hematopoietic stem cell transplantation in infants with MECOM-associated syndrome.对于 MECOM 相关综合征的婴儿,采用低强度预处理方案进行异基因造血干细胞移植是有效的。
Int J Hematol. 2023 Apr;117(4):598-606. doi: 10.1007/s12185-022-03505-7. Epub 2022 Dec 14.
2
Secondary fusion proteins as a mechanism of BCR::ABL1 kinase-independent resistance in chronic myeloid leukaemia.二次融合蛋白作为慢性髓性白血病中 BCR::ABL1 激酶非依赖性耐药的机制。
Br J Haematol. 2023 Feb;200(3):323-328. doi: 10.1111/bjh.18515. Epub 2022 Oct 20.